Stocks · News reference
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Olema Pharmaceuticals announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. As part of the appointment, O'Byrne received an employment inducement award of 650,000 stock options with an exercise price of $10.56 per share, vesting over four years with 25% vesting after one year and the remainder vesting monthly over three years.
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.
Filed: 2026-08-13 AccNo: 0001193125-26-347853 Size: 593 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits